Partners

Dr. Stefan H. Bossmann

Professor, Organic Chemistry, Kansas State University (2004 – present)
Kansas State University
Department of Chemistry and Terry C. Johnson Cancer Center;
The Midwest Institute for Comparative Stem Cell Biology;
The University of Kansas Cancer Center
213 CBC Building
Manhattan, KS 66506-0401
USA

kumc.edu/sbossmann

Personal Statement

Dr. Bossmann has 20 years of international and interdisciplinary experience in developing functional nanostructures for applications in Molecular Biosciences, Imaging, Medical Diagnostics, and Catalysis.

·         PhD in Physical Organic Chemistry (1991) from the University of Saarland, Germany, and his “habilitation” in Chemical and Process Engineering (1998) is from the University of Karlsruhe, Germany, where he served as an Assistant and Associate Professor.

·         In addition to his position of Full Professor of Chemistry at Kansas State University, Dr. Bossmann is:

–          A member of the NCI-designated University of Kansas Cancer Center (KUCC).

–          Holds the honorary title of Distinguished Professor of Kunming Medical University, Kunming, China.

Dr. Bossmann has a record of successful and productive collaborative Nano Research, beginning in 1993 at the German Elite University of Karlsruhe. Highlights this research program included:

·         Nanobiosensors for Early Detection and Imaging of Solid Tumors and (Stem)-Cell Mediated Targeting of Tumors and Infected Tissue. Dr. Bossmann’s experience in Liquid Biopsies and Targeted Drug Delivery has proven to be an excellent complement in the Nanomedicine and Nano Oncology research pursued at Kansas State University.

·         Dr. Bossmann’s convictions focus on a cell-based drug delivery and cancer immunotherapy that will provide pathways for developing personalized cancer treatment modalities.

·         Dr. Bossmann’s international collaborations includes the Liquid Biopsy Trial at The First Affiliated Hospital of Kunming Medical University (Yunnan Province, China) where his Team was able to enroll 15,000 patients in 2015 and 2016; with the trial successfully validating the protease signatures for 11 types of solid tumors.